Promedix
Portland, US · Founded 2018 · Oregon corporation · 2 known investors
ProMedix develops the PeriFRL Circulatory Dysfunction Monitor, a device that digitally measures capillary refill time (CRT) to provide standardized, noninvasive monitoring of peripheral perfusion for early sepsis detection and resuscitation. The technology is aimed at clinicians and hospital systems to identify conditions such as septic shock, dehydration, hemorrhage, and cardiogenic shock at the bedside.
BiotechDigital HealthHardwareMedical Devices
Founders & leadership
MH
Matthew HansenCo-Founder
SB
Steven BakerExecutive
SF
Scott FilerExecutive
DS
David SheridanCo-Founder
RJ
Robert JenksExecutive
AK
Andrew KiblerExecutive
Investors · 2
Reported raises · per SEC filings
Form D private placements$922.8K disclosed across 4 rounds · 2021–2024
▶$200KraisedDec 2024 · 1 investors · BiotechnologyRule 506(b)
▶$200KraisedDec 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthew HansenExecutive Officer, Director
- Steven BakerExecutive Officer
- Scott FilerExecutive Officer, Director
- David SheridanExecutive Officer, Director
- Robert JenksExecutive Officer
- Offering amount
- $200K
- Amount sold
- $200K
- First sale
- Dec 2024
- Incorporated
- Corporation, Oregon
- Federal exemptions
- 06b
▶$162.8KraisedSep 2023 · 3 investors · BiotechnologyRule 506(b)
▶$162.8KraisedSep 2023 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David SheridanExecutive Officer, Director
- Steven BakerExecutive Officer
- Matthew HansenExecutive Officer, Director
- Scott FilerExecutive Officer, Director
- Offering amount
- $162.8K
- Amount sold
- $162.8K
- First sale
- Oct 2022
- Incorporated
- Corporation, Oregon
- Federal exemptions
- 06b
▶$310KraisedSep 2023 · 4 investors · BiotechnologyRule 506(b)
▶$310KraisedSep 2023 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Scott FilerExecutive Officer, Director
- David SheridanExecutive Officer, Director
- Steven BakerExecutive Officer
- Matthew HansenExecutive Officer, Director
- Offering amount
- $310K
- Amount sold
- $310K
- First sale
- Oct 2022
- Incorporated
- Corporation, Oregon
- Federal exemptions
- 06b
▶$250KraisedApr 2021 · 1 investors · BiotechnologyRule 506(b)
▶$250KraisedApr 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andrew KiblerExecutive Officer, Director
- David SheridanExecutive Officer, Director
- Matthew HansenExecutive Officer, Director
- Offering amount
- $250K
- Amount sold
- $250K
- First sale
- Apr 2021
- Incorporated
- Corporation, Oregon, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapRevMedx6 shared keywordsRevMedx develops hemorrhage-control medical devices, including the XSTAT expanding-sponge injector for junctional bleeding, ratcheting TX tourniquets, and compression wraps. Its products serve licensed medical professionals, first responders, and military users such as US Special Operations Forces.
Trimedx6 shared keywordsTrimedx (TMX) provides clinical engineering and asset management services for health systems, using an AI-based performance intelligence platform combined with embedded engineers, advisors, and cybersecurity analysts. Its services maintain medical device uptime, inform capital and lifecycle decisions, and secure connected devices across hospital operations.
Companies competing with Promedix for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Promedix do?
- ProMedix develops the PeriFRL Circulatory Dysfunction Monitor, a device that digitally measures capillary refill time (CRT) to provide standardized, noninvasive monitoring of peripheral perfusion for early sepsis detection and resuscitation. The technology is aimed at clinicians and hospital systems to identify conditions such as septic shock, dehydration, hemorrhage, and cardiogenic shock at the bedside.
- Who are Promedix's investors?
- Promedix's investors include Elevate Capital, Ideaship.
- How much funding has Promedix raised?
- Promedix has disclosed $922.8K raised across 4 rounds.
- Where is Promedix headquartered?
- Promedix is headquartered in Portland, US.